Xtandi Gets Speedy Approval; Medivation/Astellas Already Prepped For Launch

FDA announced approval of Medivation/Astellas’ androgen receptor inhibitor Xtandi (enzalutamide) a little over three months after the NDA for metastatic castration-resistant prostate cancer was submitted, and the sponsors expect to begin promotions shortly after the U.S. Labor Day holiday.